TSS
TRIL

Two Sigma Securities’s Trillium Therapeutics Inc. TRIL Stock Holding History

Two Sigma Securities’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,947
Closed -$13K – 2529
2019
Q1 		$13K Buy
+18,947
New +$23.2K ﹤0.01% 1710

Other funds holding TRIL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RIA
Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Two Sigma Securities's TRIL Position: Q2 2019 in Review

Two Sigma Securities sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2019, closing a stake of 18,947 shares — an estimated $13K sold.

Two Sigma Securities first reported a position in TRIL in Q1 2019 and held it in 1 quarter. The position peaked at $13K in Q1 2019. 19 funds tracked by Wall St. Rank hold TRIL as of Q2 2019.

  • Two Sigma Securities reported no remaining Trillium Therapeutics Inc. position as of Q2 2019 after selling out during the quarter.
  • Two Sigma Securities sold 18,947 Trillium Therapeutics Inc. shares in Q2 2019, an estimated $13K.
  • Two Sigma Securities first reported a position in Trillium Therapeutics Inc. in Q1 2019 and held it in 1 quarter.
  • Two Sigma Securities's Trillium Therapeutics Inc. position peaked at $13K in Q1 2019.
  • 19 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2019.

Based on Two Sigma Securities's 13F filing for Q2 2019, filed 14 Aug 2019.